11. Sources and clinical references

• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Prevention, Diagnosis, and Management of COPD — 2026 Report (v1.3, released 8 December 2025); GOLD group E denotes ≥1 moderate or severe exacerbation per year; eosinophil-guided biologic therapy (e.g. dupilumab, mepolizumab). Verify the current release at time of use.
• Anthonisen criteria — the three cardinal exacerbation symptoms (increased dyspnea, sputum volume, and sputum purulence).
• Home-oxygen and inhaler-technique clinical guidance; COPD action-plan (green/yellow/red) frameworks (verify current source).
• CMS Medicare Benefit Policy Manual (Pub. 100-02), Chapter 7 — Home Health Services. Observation and assessment, teaching and training, and management and evaluation of the plan of care.
• 42 CFR Part 484 — Conditions of Participation for Home Health Agencies; comprehensive assessment and care planning.
• CMS OASIS-E2 Guidance Manual, effective April 1, 2026 — relevant respiratory items.
• Community Health Accreditation Partner (CHAP) Standards of Excellence for Home Health. [Agency-fill: insert exact title, version, section, and date.]

Standing flags. Display number is provisional; the stable overlay code is the key. The CHAP citation is agency-fill — insert the exact title, version, section, and date. Verify each pinned guideline against the current published edition at time of use.